Search the Newsreel

Why Microbix Biosystems Inc. stock plummeted yesterday

Transcript : Microbix Biosystems Inc., Q3 2026 Earnings Call, Aug 13, 2026

Microbix Biosystems Q3 2026 Earnings Call Transcript

Earnings Flash (MBX.TO) Microbix Biosystems Inc. Reports Q3 Revenue C$4.1M

Microbix Biosystems Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended June 30, 2026

Why Microbix Biosystems Inc. stock is rising today

Truist Adjusts Price Target on MBX Biosciences to $88 From $70, Maintains Buy Rating

Truist Securities has increased its price target for MBX Biosciences to $88, up from the previous $70, while reiterating a Buy rating on the company's stock. This adjustment reflects a more optimistic outlook by the analyst firm regarding MBX Biosciences' future performance.

OrbiMed trims MBX Biosciences (MBX) position to 6.4% after share sales

OrbiMed Advisors and its affiliates have reduced their beneficial ownership in MBX Biosciences (MBX) to 6.4%, down from a previous stake, following a series of open-market share sales between June 29 and August 7, 2026. The sales, executed at prices ranging from $53.48 to …

MBX Biosciences, Inc. $MBX Stock Holdings Raised by The Manufacturers Life Insurance Company

MBX Biosciences (NASDAQ:MBX) Lowered to "Sell" Rating by Wall Street Zen

Wall Street Zen has downgraded MBX Biosciences (NASDAQ:MBX) from a "Hold" to a "Sell" rating, despite a broader "Moderate Buy" consensus among other analysts with an average price target of $73.38. MBX shares opened at $67.82, showing a 1.1% increase, but the company remains …

What's Going On With Microbix Biosystems Inc. Stock Friday?

MBX Biosciences, Inc. Stock 12‑Month Price Target Raised to $84.8, Implies 26% Upside

Analysts have raised their average 12-month price target for MBX Biosciences, Inc. stock from $80.4 to $84.8, suggesting a 26% potential upside from its August 5th closing price. The consensus rating from 11 analysts remains a "Buy," with no "Hold" or "Sell" recommendations.

Why Microbix Biosystems Inc. stock is plummeting today

MBX Biosciences (Nasdaq: MBX) Q2 loss deepens as cash runway extends to 2029

MBX Biosciences reported a deepened net loss of $37.1 million for Q2 2026, compared to $19.4 million in Q2 2025, driven by increased R&D and G&A expenses. Despite the loss, the company's cash and marketable securities of $418.6 million are expected to fund operations …

MBX Biosciences, Inc. (MBX) stock price, news, quote and history

MBX Biosciences, Inc. (MBX) stock is currently trading at 66.65 USD, down 0.69% as of 14:23:14 GMT-4. The company is a clinical-stage biopharmaceutical firm focused on developing precision peptide therapies for endocrine and metabolic disorders, with lead candidates in Phase 3 and Phase 2 …

MBX Biosciences, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026

Earnings Flash (MBX) MBX Biosciences Posts Q2 Net Loss $0.78 a Share, vs. FactSet Est of $0.63 Loss

MBX Biosciences (MBX) reported a Q2 net loss of $0.78 per share, which is wider than the FactSet estimate of a $0.63 loss per share. This financial update was published on August 6, 2026, and also noted a subsequent decline in MBX Biosciences shares. …

MBX Biosciences posts Q2 loss, advances obesity pipeline By Investing.com

MBX Biosciences Inc. (NASDAQ:MBX) reported a Q2 loss of $0.78 per share, with net loss widening to $37.1 million due to increased R&D and administrative expenses. Despite the loss, the clinical-stage biopharmaceutical company made progress in its pipeline, including positive initial Phase 1 data …

An MBX Biosciences obesity candidate showed 7% mean weight loss in 8 weeks

MBX Biosciences reported Q2 2026 financial results and pipeline updates, highlighting preliminary Phase 1 data for its obesity candidate MBX 4291, which showed a mean weight loss of 7% at eight weeks. The company also nominated two new once-monthly obesity candidates, MBX 6180 and …

MBX Biosciences 2Q 2026: Net loss $(37.1M), EPS $(0.78) — 10-Q Summary

MBX Biosciences, Inc. reported a wider net loss in Q2 2026, totaling $(37.1M) or $(0.78) per share, compared to $(19.4M) or $(0.58) per share in the prior year. The company, which has no product revenue and is funded by equity offerings, highlighted clinical progress …

MBX Biosciences Shares Lower After Q2 Loss Widens

MBX Biosciences (MBX) shares dropped by approximately 1.0% in Thursday trading following the announcement of its Q2 results, which reported a widened loss. The article from MT Newswires indicates that further details are available for subscribers only.

MBX Biosciences (Nasdaq: MBX) widens Q2 loss but holds $418.6M cash

MBX Biosciences (MBX) shares dropped by approximately 1.0% in Thursday trading following the announcement of its Q2 results, which reported a widened loss. The article from MT Newswires indicates that further details are available for subscribers only.

MBX Biosciences (MBX) Earnings Date and Reports 2026

Insider Selling: MBX Biosciences (NASDAQ:MBX) Insider Sells $24,334.90 in Stock

MBX Biosciences insider Salomon Azoulay sold 370 shares worth $24,334.90 to cover tax withholding obligations from vested equity awards, reducing his stake by 2.51%. The company's stock, NASDAQ:MBX, traded down $3.22 to $67.48 on Wednesday, though it remains near its 12-month high. Analyst sentiment …

MBX Biosciences (MBX) CMO sells 370 shares to cover RSU taxes

MBX Biosciences' Chief Medical Officer, Salomon Azoulay, sold 370 shares of common stock on August 4, 2026, at a weighted average price of $65.77 per share. This transaction was executed to cover tax obligations arising from the vesting of restricted stock units, as part …

MBX Biosciences (NASDAQ:MBX) Reaches New 52-Week High - Still a Buy?

MBX Biosciences (NASDAQ:MBX) recently hit a new 52-week high, trading at $71.12 before settling at $70.70. The company maintains a "Moderate Buy" consensus rating from analysts with an average price target of $71.12. Institutional investors have also increased their holdings in MBX Biosciences during …

Mbx Biosciences stock hits all-time high of 69.5 USD By Investing.com

MBX Biosciences stock has reached an all-time high of $69.50, reflecting a 414% total return over the past year and a 104% year-to-date surge. While analysts have revised earnings upwards, InvestingPro's Fair Value analysis suggests the stock might be slightly overvalued. The company recently …

MBX Biosciences, Inc. (MBX) awards CFO 130,000 options and 28,000 RSUs

MBX Biosciences, Inc. (MBX) has awarded its Chief Financial Officer, John W. Smither, 130,000 stock options and 28,000 restricted stock units (RSUs) on August 3, 2026. The RSUs vest 25% annually from July 2027 to 2030, while the stock options, with an exercise price …

MBX Biosciences, Inc. (MBX) grants CEO major option and RSU awards

MBX Biosciences, Inc. (MBX) reported that its President and CEO, Steven L. Hoerter, received significant equity awards on August 3, 2026. These awards include stock options for 331,000 shares with an exercise price of $64.41 and 71,000 restricted stock units (RSUs). Both the options …

MBX Biosciences (NASDAQ:MBX) Sets New 52-Week High on Analyst Upgrade

MBX Biosciences (NASDAQ:MBX) reached a new 52-week high after Mizuho raised its price target from $57 to $91 and maintained an outperform rating. The company currently has an average "Moderate Buy" rating and an average price target of $71.12 from analysts. Several institutional investors …

MBX Biosciences, Inc. $MBX Shares Purchased by Stempoint Capital LP

Stempoint Capital LP significantly increased its stake in MBX Biosciences, Inc. (NASDAQ:MBX) by 535.8% in the first quarter, making MBX Biosciences its 8th largest holding. Other institutional investors like Russell Investments Group Ltd. and GF Fund Management also adjusted their positions. Analysts have issued …

BlackRock (MBX) discloses 5.5% beneficial ownership in MBX Biosciences common stock

BlackRock, Inc. has reported a beneficial ownership of 5.5% in MBX Biosciences Inc.'s common stock, equivalent to 2,628,181 shares. This disclosure was made via a Schedule 13G filing, indicating a passive investment. BlackRock holds sole voting power over 2,583,923 shares and sole dispositive power …

MBX Biosciences (NASDAQ:MBX) Trading 8.5% Higher on Analyst Upgrade

MBX Biosciences (NASDAQ:MBX) saw its shares increase by 8.5% following an analyst upgrade from Mizuho, which raised its price target from $57 to $91 and maintained an "outperform" rating. The clinical-stage biopharmaceutical company holds a consensus "Moderate Buy" rating from analysts, with an average …